GeneOne Life Science Inc (011000) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeneOne Life Science Inc (011000) has a cash flow conversion efficiency ratio of -0.056x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.84 Billion ≈ $-1.92 Million USD) by net assets (₩51.15 Billion ≈ $34.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 011000 company net worth for the company's overall valuation and market capitalisation.
GeneOne Life Science Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how GeneOne Life Science Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GeneOne Life Science Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneOne Life Science Inc ranked by their cash flow conversion efficiency. Explore GeneOne Life Science Inc (011000) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DKLS Industries Bhd
KLSE:7528
|
0.017x |
|
Cpt Drives & Power Pcl
BK:CPT
|
-0.152x |
|
Pelat Timah Nusantara Tbk
JK:NIKL
|
0.015x |
|
Youlife Group Inc. American Depositary Shares
NASDAQ:YOUL
|
N/A |
|
Shenzhen Zhongheng Huafa Co Ltd Class B
SHE:200020
|
-0.034x |
|
Dongil Metal Co. Ltd
KQ:109860
|
-0.006x |
|
Laird Superfood Inc
NYSE MKT:LSF
|
0.006x |
|
Sportshero Ltd
AU:SHO
|
-0.448x |
Annual Cash Flow Conversion Efficiency for GeneOne Life Science Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of GeneOne Life Science Inc from 2013 to 2025. View current stock price of GeneOne Life Science Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩40.90 Billion ≈ $27.72 Million |
₩-16.54 Billion ≈ $-11.21 Million |
-0.404x | -115.61% |
| 2024-12-31 | ₩85.61 Billion ≈ $58.01 Million |
₩-16.06 Billion ≈ $-10.88 Million |
-0.188x | +3.82% |
| 2023-12-31 | ₩111.49 Billion ≈ $75.55 Million |
₩-21.74 Billion ≈ $-14.74 Million |
-0.195x | -46.78% |
| 2022-12-31 | ₩181.47 Billion ≈ $122.98 Million |
₩-24.11 Billion ≈ $-16.34 Million |
-0.133x | -462.98% |
| 2021-12-31 | ₩205.45 Billion ≈ $139.23 Million |
₩-4.85 Billion ≈ $-3.29 Million |
-0.024x | +85.39% |
| 2020-12-31 | ₩98.51 Billion ≈ $66.76 Million |
₩-15.92 Billion ≈ $-10.79 Million |
-0.162x | -206.09% |
| 2019-12-31 | ₩24.06 Billion ≈ $16.31 Million |
₩-1.27 Billion ≈ $-860.67K |
-0.053x | +78.64% |
| 2018-12-31 | ₩29.41 Billion ≈ $19.93 Million |
₩-7.27 Billion ≈ $-4.93 Million |
-0.247x | -123.54% |
| 2017-12-31 | ₩36.54 Billion ≈ $24.76 Million |
₩-4.04 Billion ≈ $-2.74 Million |
-0.111x | +68.00% |
| 2016-12-31 | ₩35.85 Billion ≈ $24.30 Million |
₩-12.39 Billion ≈ $-8.40 Million |
-0.346x | -1850.57% |
| 2015-12-31 | ₩39.44 Billion ≈ $26.73 Million |
₩778.50 Million ≈ $527.58K |
0.020x | +116.49% |
| 2014-12-31 | ₩34.73 Billion ≈ $23.54 Million |
₩-4.16 Billion ≈ $-2.82 Million |
-0.120x | -20.95% |
| 2013-12-31 | ₩23.71 Billion ≈ $16.07 Million |
₩-2.35 Billion ≈ $-1.59 Million |
-0.099x | -- |
About GeneOne Life Science Inc
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, whic… Read more